Jerry Colca, PhD has a life-long interest in the concept of metabolic syndrome and in the mechanism of action of the so-called “insulin sensitizers.” He was the pharmacology team leader at Upjohn that worked with Takeda on the selection and early development of the anti-diabetic drug pioglitazone. As co-founder of Metabolic Solutions Development Company (MSDC), he led the effort that established the mitochondrial pyruvate carrier (MPC) as an alternative target of insulin sensitizers, which has allowed the selection and development of second generation insulin sensitizers. He is currently the CSO of Cirius Therapeutics, a company focused on a finding a registration pathway to develop MSDC-0602K for the treatment of NASH.